NewLink in RM3.27 billion deal with Roche to develop cancer drug

October 20, 2014 5:27 PM

6 0

NewLink in RM3.27 billion deal with Roche to develop cancer drug

NewLink Genetics Corp said it entered into an agreement withRoche Holding AG to develop NewLink’s cancer immunotherapy, making the Ebola vaccine developer eligible to receive over US$1 billion (RM3.27 billion) in milestone payments.

Immunotherapies are a class of drugs designed to help the body’s own immune system fend off disease.

Also read: KKR buys smart meter financing firm Calvin Capital

Read more

To category page

Loading...